A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
Phase of Trial: Phase III
Latest Information Update: 16 Jan 2019
At a glance
- Drugs Upadacitinib (Primary) ; Adalimumab
- Indications Psoriatic arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT - PsA 1
- Sponsors AbbVie
- 19 Dec 2018 Planned End Date changed from 6 Sep 2023 to 24 Nov 2022.
- 21 Nov 2018 Planned End Date changed from 30 Jan 2023 to 6 Sep 2023.
- 31 Aug 2018 Biomarkers information updated